19
April 2024
Clean Power Hydrogen
plc
("CPH2", the "Company" or the
"Group")
Financial Results for the
Financial Year ended 31 December 2023
Clean Power Hydrogen plc (AIM:
CPH2), the UK-based green hydrogen technology and manufacturing
company that has developed the IP-protected Membrane-Free
Electrolyser ("MFE"), is
pleased to announce its results and report for the year ended 31
December 2023 (the "Period").
Highlights
· Solid
progress towards the commercial roll out of CPH2's MFE technology
on back of a revamped engineering team, providing new insights and
reassessment:
o Successfully ran the entire MFE110 system proving the
differentiated technology works at scale.
o Successful functional testing of the control programme for the
MFE110, enabling automatic operation and shutdown.
o Improvements and modifications to key components including
stacks, cryogenic heat exchanger and other measures enhancing
safety;
o Rigorous testing of the MFE110 has identified upgrades,
informing valuable enhancements for the MFE220 design.
· Year-end net asset position of £21m, of which £8.5m was in
cash or current asset investments (term deposits).
· £2.8m
investment in research & design in the twelve months to
December 2023.
· Entered ten-year licensing agreement with Fabrum Solutions
Ltd, a New Zealand based advanced technology developer and
manufacturer, with non-exclusive rights to manufacture and sell
membrane-free electrolysers in New Zealand and
Australia.
· In
advanced discussions with several potential partners for both new
licences and orders.
· Awarded three ISO certifications confirming CPH2's commitment
to the highest standards of health and safety, sustainability and
quality management measures within our organisation:
o ISO
45001 for Occupational Health and Safety
o ISO
14001 for Environmental Management Systems
o ISO
9001 for Quality Management Systems
Outlook
· Factory Acceptance Testing for the MFE110, the Company's first
scaled membrane free electrolyser, underway with a completion date
expected in the next three months.
· Completion and delivery of the MFE220, CPH2's 1MW system for
its longstanding customer Northern Ireland Water, expected within
the next twelve months.
Jon
Duffy, CPH2 CEO commented:
"2023 has been a year of further progress for CPH2, both
operationally and technically. Our focus has centered on developing
our unique technology for commercialisation, ensuring safety and
scalability through rigorous testing of the MFE110. The successful
running of the entire MFE110 system, producing separated hydrogen
and oxygen gases, stands as a key milestone for CPH2, proving our
differentiated technology works at scale.
I
would like to thank our shareholders who have been patient and
supportive as we approach the final stages of testing. I firmly
believe that our methodical and focused approach to ensuring the
technology is both safe and scalable means that we are well
positioned to take meaningful strides once commericialisation is
achieved. Collaborating closely with our license partners and
customers, this year marks another encouraging step toward our
ambitious goal of achieving 4GW of annual production by the end of
2030.
I
extend heartfelt thanks to our team for their hard work, dedication
and enthusiasm over the past year and look forward to a positive
year ahead."
Annual Report
The Annual Report will be available
on the Company' website today (https://www.cph2.com) and
hard copies are expected to be posted to Shareholders on 10 May
2024.
For
more information, please contact:
Clean Power Hydrogen plc
|
via Camarco
|
Jon Duffy, Chief Executive
Officer
|
|
James Hobson, Chief Financial
Officer
|
|
|
|
Cavendish Capital Markets Limited - NOMAD &
Broker
|
|
Neil McDonald
|
+44 (0)131 220 9771
|
Peter Lynch
|
+44 (0)131 220 9772
|
Adam Rae
|
+44 (0)131 220 9778
|
|
|
Camarco PR
|
+ 44(0) 20 3757 4980
|
Billy Clegg
|
|
Owen Roberts
|
|
Lily Pettifar
|
|
To find out more, please
visit: https://www.cph2.com
Overview of CPH2
CPH2 is the holding company of Clean
Power Hydrogen Group Limited ("Clean Power") which has almost a
decade of dedicated research and product development experience.
This experience has resulted in the creation of simple, safe and
sustainable technology which is designed to deliver a modular
solution to the hydrogen production market in a cost-effective,
scalable, reliable and long-lasting manner. The Group's strategic
objective is to deliver the lowest LCOH in the market in relation
to the production of green hydrogen. CPH2 is listed on the AIM
market and trades under the ticker LON:CPH2.
Chairman's Statement
I am delighted to present the Annual
Report of Clean Power Hydrogen plc ("CPH2" or the "Company") for
the year ended 31 December 2023.
The past 12 months have formed a
year that encapsulated significant progress and challenges for
CPH2. Our technology, which remains at the heart of what we do, was
a key focus as we continued to progress the commercial roll out of
our ground-breaking Membrane-Free Electrolyser ("MFE"). This
focused approach to getting our technology right has put us in a
strong position as we enter 2024 and look to target the growing
hydrogen market with our unique product.
As we completed CPH2's first full
year as a listed entity, what drives us remains the belief that
green hydrogen is a significant solution to reducing carbon
intensity across a multitude of industries including the transport
sector. It is fair to say that the global focus on this has not
abated during the year and importantly from a UK Government
perspective, there is strong support for our operations. Indeed,
this support was felt recently as we had the pleasure of hosting
political leaders including Minister for Energy Efficiency and
Green Finance, Lord Callanan, and the Rt Hon Edward Miliband,
Labour MP for Doncaster North and Shadow Secretary of State for
Energy Security and Net Zero.
The green hydrogen market, a truly
emerging economy in itself, has battled its own headwinds in the
past year. While the IEA pointed to the potential annual
low-emission hydrogen production of 38 million tonnes in 2030 being
50% above its 2022 estimate, only 4% of this potential production
has taken final investment decision ("FID"). Practical challenges
with green hydrogen projects have been widely reported due to
technology not being fully robust prior to site deployment,
electrolyser reliability and performance issues, as well as
commissioning challenges. It is times like these that Government
support is crucial in getting projects moving and it has been
encouraging to see the US Hydrogen Production Tax Credit, the EU
Important Projects of Common European Interest and the UK Low
Carbon Hydrogen Business Model address this to some
extent.
The strategic position of CPH2 and
its technology in the hugely exciting hydrogen market is also a
reason to be positive. Our patented and containerised technology
offers a mobile and licensable solution that can fit within a huge
range of industry solutions. As we sit at the edge of
commercialisation, we remain very optimistic of our future and
ability to grow into this nascent market.
Board and Senior
Management
In completing our first full year as
a listed Company, I take this opportunity to recognise and thank my
fellow Directors for their work over the year. We retain a strong,
active and engaged Board, collectively sharing a passion for CPH2
to reach its full potential within the hydrogen economy. With this,
our focus on Environmental, Social and Governance ("ESG") has been
of particular importance and we continue to work closely with local
communities, educational establishments and charities.
Our Senior Management Team has been
strengthened during the period, notably in early 2023 we appointed
Chief Technology Officer ("CTO"), Paul Cassidy, whose extensive
chemical engineering and licensing knowledge has been a significant
catalyst in the successful development of CPH2's Membrane Free
Electrolyser during the year. We continue to take the governance of
our Company extremely seriously and strive to improve with every
challenge and opportunity that arises.
Outlook
While the past year has been one of
good progress, we have also experienced challenges around
commercialising our technology. As many who have followed the
sector will understand, the complexities of commercialising unique
and innovative design are vast but it is encouraging to see that
significant progress has been made. The revamped engineering team
has injected experience and professionalism into the Company,
transforming the quality of engineering output. The levels at which
the team have tirelessly worked at overcoming challenges,
successfully progressing CPH2's MFE electrolyser in the year have
been truly impressive.
As we look to the future, I know
that CPH2 sits in an extremely strong position, poised to realise
the significant value within the Company. As we continue on our
path to commercialisation and beyond, I would like to thank
everyone for their efforts in the past year and to our shareholders
who have supported us throughout the period.
Christopher Train
Chair
Chief Executive's
Review
The past year has seen significant
progress both operationally and technically for CPH2. Our key focus
has been on developing our technology for commercialisation in a
safe and scalable manner.
Technology
The catalyst for strong progress and
advances on the technology during the year has undoubtedly been the
revamped engineering team. During the year the engineering function
has been rebuilt into a stronger, more experienced and professional
team. This approach has led to a substantial improvement and a
methodical approach to identifying solutions to the challenges
faced. This has proved to be transformational for our progress on
the technology path, and I am continually encouraged and more
confident in our path forwards as a result.
Throughout the period, there has
been extensive testing of the electrolyser units. In November 2023,
we successfully ran our development unit, the MFE110, producing
separated hydrogen and oxygen gases at its expected capacity,
proving the IP-protected technology works at scale. The MFE110
contains 125kW stacks, the same sized stacks which will be used for
the MFE220, our commercial 1MW containerised system. As we
reported, however, we ceased the full Factory Acceptance Testing
("FAT") when it became apparent that we needed to upgrade the
control mechanism and the venting procedures.
Since then, we have been working in
conjunction with various third-party experts (including Lagan MEICA
Limited and Cepha Controls Limited) and registered bodies to ensure
that we not only have a successful FAT on the MFE110 but that we
also build in all necessary controls and designs into our
commercial flagship product, the MFE220.
While we had originally hoped for a
successful FAT at the start of Q2 2024, we now expect this to be
completed within the next three months. I am both cognisant and
sympathetic to our stakeholders who have been awaiting the FAT,
however I firmly believe that our methodical and focused approach
to getting our technology right means that we are extremely well
positioned to push forward in a meaningful way once
commercialisation is achieved.
In the latter stages of 2023, we
began work on getting our two proprietary technology components,
the stacks and the cryogenic heat exchanger, CE marked. We
anticipate these being certified by the end of Q2 2024. We continue
to ensure that our technology is protected by both patents and
Intellectual Property ("IP"), , applying for new patents in
multiple jurisdictions.
We are committed to developing a
safe, sustainable product and our priority going forward continues
to be delivering our MFE technology, reaching
commercialisation.
Operational
Earlier in the year we were awarded
three ISO certifications for Occupational Health and Safety (ISO
45001), Environmental Management Systems (ISO 14001), and Quality
Management Systems (ISO 9001). The certificates prove our
dedication to upholding the highest standards of health and safety,
sustainability, and quality management measures in the
business.
Commercial update
We are in a strong position
commercially, with the Company's pipeline and order book expected
to grow further following the successful commercialisation of our
technology. We continue to work in tandem with our licence partners
and customers. Through our differentiated commercial strategy we
are aiming for 3GW of annual production through licensing and 1GW
of production through manufacturing at CPH2 facilities. Our unique
and patented technology allows us to expand production quickly,
utilising partners, with limited capital outlay through such
deals.
During the reporting period, CPH2
achieved a significant milestone by entering into a ten-year
licensing agreement with Fabrum, an energy company specialising in
cryogenics. Under this strategic agreement, Fabrum gains rights to
manufacture MFEs at their facility in Christchurch, New Zealand.
Additionally, the licensing deal extends to a non-exclusive sales
licence for both Australia and New Zealand. Fabrum can market and
distribute these electrolysers in these regions, contributing to
the adoption of green hydrogen technology.
Fabrum will manufacture
electrolysers either in response to CPH2 orders or independently
for their own sales. This adaptability ensures efficient production
and timely delivery to meet market demands.
CPH2 also has a licensing agreement
with KCA Deutag for the manufacture of MFE units in their Bad
Bentheim facility in Germany. They will produce for orders from
CPH2 as well as their own customers. Following the initial two-year
period, they will also be able to manufacture in Oman, and sell
exclusively to certain countries in the Middle East up to 2GW over
a ten-year period. They will also manufacture and sell, on a
non-exclusive basis, to their customers in Germany, Scotland,
Denmark, and Azerbaijan up to 150MW per annum.
We are in advanced discussions with
a number of potential partners for both new licences and
orders.
People
Our people remain central to the
future success of the business. During the year we have focused on
growing our engineering and production capabilities under the
excellent guidance of Paul Cassidy, who joined in March 2023 as
CTO, and Arash Selahi, COO. There is a strong emphasis on promoting
a positive health and safety culture at every level of the
organisation, with a strong emphasis on open communication and
engagement. During 2023 there was 0.5 days in lost time incidents.
We are at the cutting edge of green hydrogen production and are
proud of the expertise and knowledge we hold within the business
backed up by a culture of innovation, passion, inclusiveness, and
sincerity.
Market
The outlook for green hydrogen
remains exceptionally promising, with an estimated $1.7 trillion in
global investments into electrolysers over the next 27 years.
Global warming and energy security are still two of the most
pressing issues we face, and with the need to reach net-zero
targets becoming ever-closer, our technology is well positioned
alongside the wider sector to help reach these goals.
The global consulting business,
McKinsey and Company, predict that clean hydrogen demand could
reach 585 million tonnes per annum by 2050. This is testament to
why getting our technology right now is far more important than
ever.
CPH2 occupies a distinctive position
to meet the growing demand for reliable, affordable, and
sustainable fuel and we are committed to making a positive impact
to benefit all. Our strategic aim is to have 4GW of annual
production by the end of 2030. Our patented technology means we can
licence our production to third parties. Of the 4GW, we expect 1GW
will be manufactured by CPH2 and 3GW will be manufactured under
licence.
Outlook
2024 will be a truly
transformational year for CPH2 as we look to commercialise our technology. The upcoming Factory
Acceptance Test of the MFE110, has become an important milestone
for our stakeholders. Following this, the focus will shift to the
completion of the MFE220 orders already under contract. Once we
have demonstrated that our MFE technology operates effectively, we
will look to commercialise our technology, building the customer
order book and focusing on scaling production. That is when our
dual model of production and licensing will start to prove itself.
We will only scale at a pace that is truly sustainable.
Looking to this year, 2024 will be
about building solid foundations to include supply, engineering,
production, finance, sales and marketing.
The long-term possibilities for CPH2 are too significant to risk on
short-term expediency. To put McKinsey's demand projection of 585
million tonnes of clean hydrogen annually into context - that is
the equivalent of over 3.5 million 1MW electrolysers.
I would like to thank our
incredible team at CPH2 for their hard work, dedication and
enthusiasm over the past year and look forward to a positive year
ahead. I would also like to thank our shareholders for supporting
our vision to improve the world we live in and make tangible steps
towards net-zero.
Jon Duffy
Chief Executive Officer
Technology Review
Introduction
Technologically, we have made
extensive progress throughout the period, overseen by Paul Cassidy,
who joined as CTO in March 2023. Paul's wealth of knowledge and
track record of scaling up technologies from the laboratory to
implementation at a commercial scale has been an asset to the CPH2
team and by challenging the previously held collective
understanding of the technology, this has led to critical
assessment and improvements in many areas. The appointment of Paul
has seen CPH2 build a stronger, more experienced engineering team
with excellent industry experience and professional standards,
accelerating our internal engineering procedures, commissioning
processes and safety standards.
A diversity of new experience and
new ideas within our engineering team has led to new R&D
innovations and opportunities for efficiencies, enhancing our
technology pathway. Throughout the period, we have improved the
product design programme with a better understanding of levels of
safety. The revamped team also identified potential issues and
bottlenecks in relation to the balance of plant which the Company
was not previously aware of, all of which have been or are being
resolved. By encouraging innovative and collaborative thinking, we
have created a stronger, more robust electrolyser design which
underscores our confidence in the technology and the potential of
its future.
Progress during the
year
Tangible progress has been made
throughout the year, with our entire MFE110 system successfully
running from September to November 2023, producing separated
hydrogen and oxygen gases. The MFE110 contains 125kW stacks, the
same sized stacks that will be used for the MFE220. The efficient
operation of these stacks has inspired further opportunities for
improvements to the balance of plant design to support higher
performance for the stacks and ultimately more output.
The ongoing commissioning process
has given extensive operability and design feedback which has led
to the redesign of some components. This process has been conducted
in a methodical way and gives us confidence in our ability to fully
commercialise the MFE.
Although the November 2023 operation
proved that the technology route is sound and confirmed the design
of key equipment, the level of manual intervention by the operators
was greater than a commercial product could sustain, which is
intended to operate autonomously. After the testing, a work
programme was undertaken to revisit the control system to minimise
manual intervention and improve the automated shutdown
functions.
Post period end, we completed the
functional test of the control programme for the MFE110. This
control programme is installed in the Programmable Logic Controller
("PLC") which automatically operates the MFE110 and controls
elements such as start-up, normal operation, shutdown, and
emergency shutdown. The revision of the control programme, and
particularly the safety shutdown programme logic, has addressed the
issue which originally caused the pausing of the MFE110 FAT in
November 2023, and successful completion of the logic control has
allowed the Company to progress to the final stages towards FAT
test of the MFE110.
During the year a work programme was
undertaken to improve the quality and repeatability of stack
manufacture through adjusting the manufacturing method. This has
resulted in fewer quality failures and greater repeatability in
achieving essential quality parameters. This has been conducted
alongside a programme to gain CE certification for the
stacks.
In regards to developments in
safety, the Hazard and Operability Study ("HAZOP") and Layer of
Protection Analysis ("LOPA") has been revisited by independent
party and implemented findings. The implemented changes to the
control system of the electrolyser described above ensures
compliance with international functional safety standards IEC-61508
and IEC-61511.
A siting study and consequence
analysis for the electrolyser has been conducted by an independent
third party and the findings have been incorporated into CPH2
safety guidelines.
On the MFE220, the design of the
system is being finalised and orders have been placed for remaining
equipment. A new container layout has been developed for the MFE220
to assist with improved operability, access and ease of
shipping.
The design of cryogenic heat
exchanger has been optimised for the MFE220 to improve thermal
performance, mechanical robustness, and consistency in manufacture.
A CE marking process of the cryogenic heat exchanger component is
also being undertaken.
Outlook
Technology is at the heart of what
we do. We are striving to deliver the unique Membrane-Free
Electrolyser which produces green hydrogen in a simple, safe, and
sustainable manner, and at any scale. Looking ahead, our focus is
on completing the MFE110 FAT proving our ability to deliver a
robust, industry-ready commercial product. The MFE110 FAT is a
component level demonstration of the MFE220 commercial product
which will be delivered to our first customer within the next
twelve months.
Upon commercialisation of our MFE
technology, we will continue to invest in R&D, enhancing the
operational efficiencies of CPH2 technology through updates to key
stacks and cryogenic heat exchanger components. We will continue to
invest in R&D related to safety and progress engineering
through roll out of build packs for our licensees.
Financial Review
Introduction
During the course of 2023, CPH2 made
significant progress in advancing the Company's technology towards
a commercial offering. The Group finances were carefully managed to
enable the technology to develop at pace, yet the overall spend of
the organisation was otherwise controlled to conserve its resources
whilst the Company is pre-revenue.
Recognising the importance of
ensuring resources are focused and not diluted was also a theme in
2023. Where possible we have aligned our activities aroundCPH2's
core focus. During the year, we negotiated the exit of a contract
for delivery of a MFE110 loan electrolyser and a 1MW MFE220 to a
customer in Paraguay, upon the Company's decision to focus its
engineering and installation resources on its current partners and
its long-standing customer Northern Ireland Water. As stated in the
Chief Executive's Review a conscious decision was made to pause
entering into new customer contracts while we focus on moving the
technology to being commercially ready.
For the 2023 financial year,
administrative expenses of £5.4m increased moderately by £0.6m from
the previous year (2022: £4.8m), reflecting 12 months of post IPO
expansion (2022: 10 months). Whilst there was a focus recruiting
more experienced engineering staff this was moderated by CPH2's
expected staff turnover and undertaken in a controlled
manner.
Operating loss before tax was £5.4m
for the 2023 financial year (2022: £3.8m), reflecting the moderate
increase in administrative expenses mentioned above, as well as the
one-off exceptional credit of £1m in the comparative year, due to a
share-based credit as well as expensed IPO costs as reported last
year.
R&D tax credits from the 2023
financial year onwards will be recognised in the year which the
credit remains applicable to, whereas up until 2022 R&D tax
credits have been recognised only on receipt. This has resulted in
the 2023 financial year including a R&D tax credit for
expenditure incurred in the 2022 financial year (2022: £0.5m)
already received and a R&D tax credit accrued for expenditure
incurred in the 2023 financial year.
Capitalised development costs for
the year ended 31 December 2023 increased by £2.0m (2022: £4.2m)
and there was an increase of £1.6m in spend on plant and equipment
(2022 £0.3m) of which £1.0m was in relation to expenditure towards
a demonstrator electrolyser. Deferred income has reduced by £0.8m
to £1.8m as at 31 December 2023 (2022: £2.6m) on return of certain
customer deposits as mutually agreed.
Cash
We remain in a solid financial
position with £8.5m cash and term deposits as at 31 December 2023
(Dec 2022: £15.3m). The net operating cash spend was £3.6m for the
year, a 50% reduction compared to the previous year (2022: £7.2m)
reflecting a focus on progress with the technology and cost
control. Cash spend on investment in development work and patent
applications was £2.8m.
Outlook
CPH2 is in a solid financial
position with £8.5m in cash and term deposits, and £1.2m liquid
investments at 31 December 2023. As we progress our technology in
the fastest route to commercialisation, we will continue to ensure
that the financial resources are diligently managed and focused on
the Company's core priorities.
James Hobson
Chief Financial
Officer
Consolidated Statement of Comprehensive
Income
FOR THE YEAR ENDED 31 DECEMBER 2023
|
|
2023
|
2022
|
|
|
£'000
|
£'000
|
Administrative expenses excluding
exceptional items
|
|
(5,423)
|
(4,765)
|
Exceptional net credit
|
|
-
|
986
|
Total administrative
expenses
|
|
(5,423)
|
(3,779)
|
Operating loss
|
|
(5,423)
|
(3,779)
|
Finance income
|
|
345
|
216
|
Finance expense
|
|
(49)
|
(55)
|
Loss before taxation
|
|
(5,127)
|
(3,618)
|
Taxation
|
|
1,012
|
174
|
Loss for the financial year
|
|
(4,115)
|
(3,444)
|
Other comprehensive (expense)/income
|
|
|
|
Items that may be reclassified
subsequently to profit or loss:
|
|
|
|
Foreign currency translation
differences
|
|
9
|
(19)
|
Fair value decrease in respect of
investments
|
|
(438)
|
(3)
|
Total comprehensive expense for the year
|
|
(4,544)
|
(3,466)
|
Basic and diluted earnings per share (pence)
|
|
(1.54)
|
(1.35)
|
Consolidated Statement of Financial Position
AS
AT 31 DECEMBER 2023
|
|
|
31 December
2023
|
31
December 2022
|
|
|
|
£'000
|
£'000
|
Assets
|
|
|
|
|
Non-current assets
|
|
|
|
|
Intangible assets
|
|
|
7,614
|
5,476
|
Property, plant and
equipment
|
|
|
2,642
|
1,387
|
Fair value through OCI
investments
|
|
|
1,059
|
1,497
|
Other receivables
|
|
|
120
|
120
|
|
|
|
11,435
|
8,480
|
Current assets
|
|
|
|
|
Inventories
|
|
|
3,155
|
2,363
|
Trade and other
receivables
|
|
|
1,449
|
3,239
|
Current asset investments
|
|
|
6,000
|
13,500
|
Cash and cash equivalents
|
|
|
2,468
|
1,790
|
|
|
|
13,072
|
20,892
|
Total assets
|
|
|
24,507
|
29,372
|
Liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
|
Trade and other payables
|
|
|
(1,037)
|
(844)
|
Deferred income
|
|
|
-
|
(1,858)
|
Lease liabilities
|
|
|
(128)
|
(121)
|
|
|
|
(1,165)
|
(2,823)
|
Non-current liabilities
|
|
|
|
|
Deferred income
|
|
|
(1,780)
|
(641)
|
Lease liabilities
|
|
|
(609)
|
(737)
|
|
|
|
(2,389)
|
(1,378)
|
Total liabilities
|
|
|
(3,554)
|
(4,201)
|
Net
assets/(liabilities)
|
|
|
20,953
|
25,171
|
Equity
|
|
|
|
|
Called up share capital
|
|
|
2,682
|
2,654
|
Share premium account
|
|
|
27,707
|
27,638
|
Merger reserve
|
|
|
3,702
|
3,702
|
Currency translation
reserve
|
|
|
(6)
|
(15)
|
Accumulated loss
|
|
|
(13,132)
|
(8,808)
|
Total equity
|
|
|
20,953
|
25,171
|
Consolidated Statement of Changes in Equity
FOR THE YEAR ENDED 31 DECEMBER 2023
|
Called up share
capital
£'000
|
Share premium
account
£'000
|
Merger
reserve
£'000
|
Foreign currency
reserve
£'000
|
Accumulated
loss
£'000
|
Total
equity
£'000
|
Balance as at 31 December
2021
|
9
|
5,545
|
-
|
4
|
(5,910)
|
(352)
|
Loss for the financial
year
|
-
|
-
|
-
|
|
(3,444)
|
(3,444)
|
Other comprehensive
expense
|
-
|
-
|
-
|
(19)
|
(3)
|
(22)
|
Total comprehensive expense for the
year
|
-
|
-
|
-
|
(19)
|
(3,447)
|
(3,466)
|
Share based payments
|
-
|
-
|
-
|
-
|
549
|
549
|
Capital reorganisation
|
1,843
|
(5,545)
|
3,702
|
-
|
-
|
-
|
Issue of share capital
|
802
|
27,638
|
-
|
-
|
-
|
28,440
|
Total contributions by
owners
|
2,645
|
22,093
|
3,702
|
-
|
549
|
28,989
|
Balance as at 31 December 2022
|
2,654
|
27,638
|
3,702
|
(15)
|
(8,808)
|
25,171
|
Loss for the financial
year
|
-
|
-
|
-
|
-
|
(4,115)
|
(4,115)
|
Other comprehensive
expense
|
-
|
-
|
-
|
9
|
(438)
|
(429)
|
Total comprehensive expense for the
year
|
-
|
-
|
-
|
9
|
(4,553)
|
(4,544)
|
Share based payments
|
-
|
-
|
-
|
-
|
229
|
229
|
Issue of share capital
|
28
|
69
|
-
|
-
|
-
|
97
|
Balance as at 31 December 2023
|
2,682
|
27,707
|
3,702
|
(6)
|
(13,132)
|
20,953
|
Consolidated Cash Flow Statement
FOR THE YEAR ENDED 31 DECEMBER 2023
|
|
2023
|
2022
|
|
Note
|
£'000
|
£'000
|
Cash flow from operating activities
|
|
|
|
Loss for the financial
year
|
|
(4,115)
)
|
(3,444)
|
Adjustment for:
|
|
|
|
Depreciation and
amortisation
|
|
413
|
249
|
Loss on disposal
|
|
-
|
5
|
Share based payments
|
|
229
|
(1,416)
|
Foreign exchange
|
|
11
|
(25)
|
Net finance income
|
|
(296)
|
(161)
|
Taxation credit
|
|
(1,012)
|
(174)
|
Changes in working capital:
|
|
|
|
Increase in inventories
|
|
(155)
|
(281)
|
Decrease/(increase) in trade and
other receivables
|
|
2,116
|
(2,361)
|
(Decrease)/increase in trade and
other payables
|
|
(526)
|
293
|
Cash used in operations
|
|
(3,335)
|
(7,315)
|
Income tax received
|
|
686
|
143
|
Net
cash used in operating activities
|
|
(2,649)
|
(7,172)
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
Current asset investments
withdrawn/(made)
|
|
7,500
|
(13,500)
|
Purchase of property, plant and
equipment
|
|
(1,595)
|
(292)
|
Purchase of intangible
assets
|
|
(2,850)
|
(4,316)
|
Purchase of investments
|
|
-
|
(1,500)
|
Net
cash generated from/(used in) investing
activities
|
|
3,055
|
(19,608)
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
Issue of share capital (net of
costs)
|
|
97
|
28,440
|
Interest received
|
|
345
|
216
|
Related party loan repaid
|
|
-
|
(382)
|
Interest paid
|
|
(49)
|
(55)
|
Payment of lease
liabilities
|
|
(121)
|
(129)
|
Net cash generated from
financing activities
|
|
272
|
28,090
|
|
|
|
|
Net
increase in cash and cash equivalents
|
|
678
|
1,310
|
Cash and cash equivalents at the
beginning of the year
|
|
1,790
|
480
|
Cash and cash equivalents at the end of the
year
|
|
2,468
|
1,790
|
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2023
1 Summary of significant
accounting policies and general information
Clean Power Hydrogen plc is a public
company incorporated in the United Kingdom and quoted on the
Alternative Investment Market ("AIM"). The registered address of
the Company is Unit D Parkside Business Park, Spinners Road,
Doncaster, England, DN2 4BL.
The summary accounts set out above do
not constitute statutory accounts as defined by Section 434 of the
UK Companies Act 2006. The summarised consolidated statement of
financial position at 31 December 2022, the summarised consolidated
income statement and other comprehensive income, the summarised
consolidated statement of changes in equity and the summarised
consolidated cash flow statement for the year then ended have been
extracted from the Group's 2022 statutory financial statements upon
which the auditor's opinion is unqualified and did not contain a
statement under either sections 498(2) or 498(3) of the Companies
Act 2006.
The summary accounts are based on the
Group financial statements have been prepared in accordance with UK
adopted international accounting standards ("IFRS") and in
accordance with the requirements of the Companies Act
2006.
Going concern
In assessing the Group's ability to
operate as a going concern, the Board have prepared cash flow
forecasts for the period to 31 December 2025 in relation to likely
future cash flows in a base case scenario, an upside scenario and a
downside scenario. The base case scenario assumes expected likely
future operations but with conservative assumptions on new sales
orders. The upside scenario considers likely future
operations but with moderate growth in new sales.
The downside scenario explores the
scenario where a fundamental technology issue is found, that would
result in delay of at least twelve months to find a solution. If
such an issue arose the Group would aim to take a number of
coordinated actions designed to reduce cash burn whilst having
sufficient capabilities to resolve the issue, including selective
disposal of assets, a cost reduction programme and other commercial
actions.
The forecasts for each of the
scenarios show that the Company and the
Group will be able to operate within the level of cash
reserves. The
Directors therefore have a reasonable expectation that the Company
and Group have adequate resources to continue in operational
existence for a period of 12 months from the date of approval of
these financial statements and consider the going concern basis to
be appropriate.